Trial Profile
A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered at Two Dose Levels.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- 15 Apr 2013 ID N01AI80057C deleted - not a trial-specific identifier.
- 01 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Sep 2009 Actual patient number (408) added as reported by ClinicalTrials.gov.